<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899857</url>
  </required_header>
  <id_info>
    <org_study_id>PERGOLA</org_study_id>
    <nct_id>NCT03899857</nct_id>
  </id_info>
  <brief_title>Pembrolizumab for Newly Diagnosed Glioblastoma</brief_title>
  <acronym>PERGOLA</acronym>
  <official_title>Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in&#xD;
      patients with newly diagnosed glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <description>To explore whether the addition of pembrolizumab to standard temozolomide-based radiochemotherapy improves the outcome of newly diagnosed glioblastoma or gliosarcoma patients, determined by the overall survival rate at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates using (i)RANO (immunotherapy response assessment in neuro-oncology) criteria</measure>
    <time_frame>From the inclusion in the study until the end of follow-up (up to approximately 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) at 6 and 12 months</measure>
    <time_frame>At 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>From the inclusion in the study until the end of follow-up (up to approximately 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of life (HRQol)</measure>
    <time_frame>From the inclusion in the study until the end of follow-up (up to approximately 36 months)</time_frame>
    <description>HRQoL will be assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) version 3. Scoring: 0 to 100. Higher scores mean a better level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of programmed cell death (PD-1) ligand 1 (PD-L1) expression levels with response to treatment and outcome</measure>
    <time_frame>From the inclusion in the study until the end of follow-up (up to approximately 36 months)</time_frame>
    <description>Expression levels of PD-L1 will be determined in the tumor tissue and correlated with response as determined by MRI and progression-free as well as overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Newly Diagnosed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide-based radiochemotherapy (TMZ/RT=&gt;TMZ) represents the standard of care for patients with newly diagnosed glioblastoma. In this study, pembrolizumab will be administered (200 mg every 3 weeks) in addition to TMZ/RT=&gt;TMZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be added to standard of care</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient has provided written informed consent prior to any study-related&#xD;
             procedure.&#xD;
&#xD;
          -  Newly diagnosed glioblastoma or gliosarcoma as confirmed by local histopathology&#xD;
&#xD;
          -  The patient is at least 18 years of age on day of signing informed consent&#xD;
&#xD;
          -  Absence of isocitrate dehydrogenase (IDH)1 R132H mutation by immunohistochemistry&#xD;
&#xD;
          -  A maximum dose of 4 mg/day dexamethasone or equivalent doses for other&#xD;
             corticosteroids, which has been stable or decreased for ≥5 days prior to start of&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patient who are treated with anticoagulants are on a stable dose for at least two&#xD;
             weeks prior to start of radiotherapy (RT)&#xD;
&#xD;
          -  The patient is male or a non-pregnant, non-lactating female&#xD;
&#xD;
          -  Females of childbearing potential must have a negative beta-human chorionic&#xD;
             gonadotropin (HCG) pregnancy test within 2 weeks prior to receiving the first dose of&#xD;
             study medication. Females must practice strict birth control using two different&#xD;
             methods (e.g. oral contraceptives in combination with barrier protection) to prevent&#xD;
             pregnancy for the duration of the study through 120 days after the last dose of study&#xD;
             medication. Males will be advised to use barrier protection starting with the first&#xD;
             dose of study therapy through 120 days after the last dose of study therapy)&#xD;
&#xD;
          -  The patient has a life expectancy of at least 3 months&#xD;
&#xD;
          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or&#xD;
             1&#xD;
&#xD;
          -  The patient shows adequate organ functions as assessed by the following laboratory&#xD;
             values within 2 weeks prior to first dose of study medication:&#xD;
&#xD;
               -  Adequate renal function determined by serum creatinine and urea &lt; 2 times the&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Adequate liver function with alanine aminotransferase (ALT), aspartate&#xD;
                  aminotransferase (AST) and alkaline phosphatase (AP) &lt; 3 times the upper limit of&#xD;
                  normal, and bilirubin value &lt; 2.5 mg/dL&#xD;
&#xD;
               -  International normalized ratio (INR) and activated partial thromboplastin time&#xD;
                  (aPTT) within therapeutic limits (according to the medical standard at the&#xD;
                  institution)&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
               -  White blood count (WBC) &gt; 3 x 10^9/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Patient is able to undergo Gd MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or&#xD;
             allergy to temozolomide (TMZ) or pembrolizumab,&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Any known IDH mutation if tested&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV), hepatitis C virus (HBV) or hepatitis C virus (HCV)&#xD;
             infection&#xD;
&#xD;
          -  Has a history of active tuberculosis (Bacillus Tuberculosis)&#xD;
&#xD;
          -  Clinically relevant acute viral, bacterial, or fungal infection&#xD;
&#xD;
          -  History of a second independent malignant disorder during the last three years except&#xD;
             non-melanoma skin cancer, in situ cervical cancer, treated superficial bladder cancer&#xD;
             or cured, early-stage prostate cancer in a patient with prostate-specific antigen&#xD;
             (PSA) level less than upper normal limit&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, long-term use of corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment.&#xD;
&#xD;
          -  Has history of, or any evidence of active, non-infectious pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or&#xD;
             anti-PD-L2 agent&#xD;
&#xD;
          -  Prior radiotherapy to the brain or interstitial brachytherapy&#xD;
&#xD;
          -  Prior chemotherapy for a brain tumor&#xD;
&#xD;
          -  Intraoperative placement of carmustine wafers (Gliadel®)&#xD;
&#xD;
          -  Prior therapy with immune checkpoint inhibitors or vaccination therapy against the&#xD;
             tumor&#xD;
&#xD;
          -  Concurrent administration of any antitumor therapy other than TMZ/RT=&gt;TMZ&#xD;
&#xD;
          -  Clinically relevant psychiatric disorders/legal incapacity or a limited legal capacity&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy&#xD;
&#xD;
          -  Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines&#xD;
             and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  Lack of safe contraception, defined as: Female participants of childbearing potential,&#xD;
             not using and not willing to continue using a medically reliable method of&#xD;
             contraception for the entire study duration, such as oral, injectable, or implantable&#xD;
             contraceptives, or intrauterine contraceptive devices, or who are not using any other&#xD;
             method considered sufficiently reliable by the investigator in individual cases.&#xD;
&#xD;
          -  Please note that female participants who are surgically sterilised / hysterectomised&#xD;
             or post-menopausal for longer than 2 years are not considered as being of child&#xD;
             bearing potential.&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant,&#xD;
&#xD;
          -  Has psychiatric or substance abuse disorders including extensive use of alcohol that&#xD;
             would interfere with cooperation with the requirements of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Roth, MD</last_name>
    <phone>+41 (0)44 255 5511</phone>
    <email>patrick.roth@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Adorjani</last_name>
    <phone>+41 (0)44 255 5511</phone>
    <email>martaandrea.adorjani@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bern / Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Zenger, MD</last_name>
      <email>franziska.zenger@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne, CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hottinger, MD</last_name>
      <email>andreas.hottinger@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Roth, MD</last_name>
      <phone>044 255 5511</phone>
      <email>patrick.roth@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>December 13, 2020</last_update_submitted>
  <last_update_submitted_qc>December 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

